In the wake of the high-profile departure of Peter Marks, M.D., Ph.D., the FDA has a new leader for its Center for Biologics Evaluation and Research (CBER). | In the wake of the high-profile departure ...

At the 2025 MM+M Transform conference on Thursday, former FDA Commissioner Scott Gottlieb critiqued the dismantling of OPDP. He said HHS has effectively “eliminated most of the group that oversees ...

Marks served as head of the FDA's Center for Biologics Evaluation and Research, which oversees the approvals of vaccines as well as other kinds of medical products that are derived from living ...